Thomas Harding - Jan 1, 2022 Form 4 Insider Report for Clovis Oncology, Inc. (CLVS)

Role
Senior Vice President and Chief Scientific Officer
Signature
/s/ Thomas C. Harding
Stock symbol
CLVS
Transactions as of
Jan 1, 2022
Transactions value $
-$19
Form type
4
Date filed
1/4/2022, 03:15 PM
Previous filing
Dec 3, 2021
Next filing
Feb 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLVS Common Stock Options Exercise +16 +1.04% 1.56K Jan 1, 2022 By wife F1
transaction CLVS Common Stock Sale -$19 -7 -0.45% $2.75* 1.55K Jan 3, 2022 By wife F2
holding CLVS Common Stock 5.4K Jan 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLVS Restricted Stock Units Options Exercise $0 -16 -9.3% $0.00 156 Jan 1, 2022 Common Stock 16 By wife F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2 Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3 On July 1, 2020, the reporting person's wife was granted 250 Restricted Stock Units. 25% of such Restricted Stock Units vested on July 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Remarks:

Senior Vice President and Chief Scientific Officer